PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Doxofylline→

Doxofylline PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
69975-86-6
Molecular formula
C11H14N4O4
Molecular weight
266.25 g/mol
Drug class
Methylxanthine bronchodilatorxanthine derivative
Mechanism of action
The exact molecular mechanism is not fully resolved. Doxofylline produces bronchodilation and has been described as modulating phosphodiesterase/cyclic-AMP signalling; unlike theophylline, it has markedly reduced affinity for adenosine receptors and does not show the same adenosine-antagonist profile.
Indications / reported uses
  • Bronchial asthma
  • Chronic obstructive pulmonary disease (COPD) and other obstructive airway conditions where doxofylline is authorised; indication and formulation differ by jurisdiction

Sources: MIMS India — Doxofylline information · PubChem — Doxofylline and ChEBI summary · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Doxofylline PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Doxofylline Permitted Daily Exposure (PDE) report (the Doxofylline PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Doxofylline Occupational Exposure Limit (OEL) report (the Doxofylline OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.